A 4250

Drug Profile

A 4250

Alternative Names: A-4250

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Albireo AB
  • Developer Albireo AB; Albireo Pharma
  • Class Antipruritics
  • Mechanism of Action Sodium-bile acid cotransporter modulators; Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis; Intrahepatic cholestasis; Alagille syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intrahepatic cholestasis; Primary biliary cirrhosis; Pruritus
  • Phase I Alagille syndrome
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 16 May 2017 Albireo Pharma has patent protection for the composition of matter and a method of use of A 4250 in Europe, Japan and World
  • 16 May 2017 Albireo Pharma receives patent allowance for the method of treatment for A 4250 for progressive familial intrahepatic cholestasis, non-alcoholic steatohepatitis and other liver diseases in USA
  • 10 May 2017 Interim adverse events data from a phase II trial in Pruritus presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top